IL270070B2 - Compounds, compositions and methods for treating or preventing acute lung injury - Google Patents

Compounds, compositions and methods for treating or preventing acute lung injury

Info

Publication number
IL270070B2
IL270070B2 IL270070A IL27007019A IL270070B2 IL 270070 B2 IL270070 B2 IL 270070B2 IL 270070 A IL270070 A IL 270070A IL 27007019 A IL27007019 A IL 27007019A IL 270070 B2 IL270070 B2 IL 270070B2
Authority
IL
Israel
Prior art keywords
pazopanib
subject
solvate
salt
day
Prior art date
Application number
IL270070A
Other languages
English (en)
Hebrew (he)
Other versions
IL270070A (enExample
IL270070B1 (en
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL270070A publication Critical patent/IL270070A/en
Publication of IL270070B1 publication Critical patent/IL270070B1/en
Publication of IL270070B2 publication Critical patent/IL270070B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL270070A 2017-04-17 2018-04-17 Compounds, compositions and methods for treating or preventing acute lung injury IL270070B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (3)

Publication Number Publication Date
IL270070A IL270070A (enExample) 2019-12-31
IL270070B1 IL270070B1 (en) 2023-05-01
IL270070B2 true IL270070B2 (en) 2023-09-01

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270070A IL270070B2 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods for treating or preventing acute lung injury

Country Status (7)

Country Link
US (3) US11166953B2 (enExample)
EP (1) EP3612184B1 (enExample)
JP (1) JP7108018B2 (enExample)
CN (1) CN110753546B (enExample)
CA (1) CA3060247A1 (enExample)
IL (1) IL270070B2 (enExample)
WO (1) WO2018195084A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US11304947B2 (en) 2020-05-22 2022-04-19 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US20130289014A1 (en) * 2010-04-27 2013-10-31 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US20160208002A1 (en) * 2013-09-30 2016-07-21 Richard H. Gomer Compositions Associated with and Methods of Managing Neutrophil Movement

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
JP5823672B2 (ja) 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
WO2013066616A1 (en) * 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Pazopanib formulation
TW201333039A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US20130289014A1 (en) * 2010-04-27 2013-10-31 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US20160208002A1 (en) * 2013-09-30 2016-07-21 Richard H. Gomer Compositions Associated with and Methods of Managing Neutrophil Movement

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPADIA ET AL,, RISK OF LIVER TOXICITY WITH THE ANGIOGENESIS INHIBITOR PAZOPANIB IN CANCER PATIENTS, 31 December 2013 (2013-12-31) *
MCMILLAN ET AL., SIGLEC-E PROMOTES 2-INTEGRIN-DEPENDENT NADPH OXIDASE ACTIVATION TO SUPPRESS NEUTROPHIL RECRUITMENT TO THE LUNG, 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
US12544377B2 (en) 2026-02-10
CN110753546B (zh) 2023-11-10
EP3612184A4 (en) 2021-01-20
US11890283B2 (en) 2024-02-06
US20210121459A1 (en) 2021-04-29
US20220040177A1 (en) 2022-02-10
JP7108018B2 (ja) 2022-07-27
CN110753546A (zh) 2020-02-04
JP2020516689A (ja) 2020-06-11
CA3060247A1 (en) 2018-10-25
EP3612184A1 (en) 2020-02-26
IL270070A (enExample) 2019-12-31
EP3612184B1 (en) 2024-06-05
IL270070B1 (en) 2023-05-01
US20240165115A1 (en) 2024-05-23
WO2018195084A1 (en) 2018-10-25
US11166953B2 (en) 2021-11-09

Similar Documents

Publication Publication Date Title
Guan et al. Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K/AKT/mTOR pathway
Wang et al. Progress in the mechanism and targeted drug therapy for COPD
US12544377B2 (en) Compounds, compositions and methods of treating or preventing acute lung injury
Lee et al. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression
Syrkina et al. Oxidant stress mediates inflammation and apoptosis in ventilator‐induced lung injury
Zhang et al. Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: Role of SIRT1/Nrf2 signaling‐modulated mitochondrial dysfunction and oxidative stress
US9913819B2 (en) Methods of treating or preventing fibrotic lung diseases
US20230050861A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
Vadász et al. Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+, K+-ATPase
Casalino-Matsuda et al. Hypercapnia suppresses macrophage antiviral activity and increases mortality of influenza A infection via Akt1
Zeng et al. Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US20170360749A1 (en) Method of preventing or treating a pulmonary disease or condition
JP2011506516A (ja) 膵嚢胞性線維症の予防および／または対症治療のための医薬組成物
US20230144457A1 (en) Methods for treating viral infections, organ injury, and related conditions
Li et al. ATF3 deficiency promotes alveolar macrophage pyroptosis in sepsis-induced acute lung injury
JP2013518061A (ja) 疾患の治療に使用される化合物
Mantell et al. Design and application of locally delivered agonists of the adenosine A2A receptor
US20220339122A1 (en) Methods for the treatment of diseases associated with dysregulated activation and recruitment of neutrophils
HK40018465A (en) Compounds, compositions and methods of treating or preventing acute lung injury
HK40018465B (en) Compounds, compositions and methods of treating or preventing acute lung injury
KR20260044678A (ko) 포비돈-프러시안 블루 나노자임을 유효성분으로 포함하는 천식의 예방, 치료 또는 개선용 조성물
Thomson Anti-Mediator Therapy